Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective.

Details

Serval ID
serval:BIB_EA604C5529C3
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective.
Journal
Thrombosis Research
Author(s)
Alatri A., Armstrong A.E., Greinacher A., Koster A., Kozek-Langenecker S.A., Lancé M.D., Link A., Nielsen J.D., Sandset P.M., Spanjersberg A.J., Spannagl M.
ISSN
1879-2472 (Electronic)
ISSN-L
0049-3848
Publication state
Published
Issued date
2012
Volume
129
Number
4
Pages
426-433
Language
english
Notes
Publication types: Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
Abstract
Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.
Keywords
Anticoagulants/adverse effects, Antithrombins/administration & dosage, Antithrombins/adverse effects, Dose-Response Relationship, Drug, Europe, Hematology/standards, Heparin/adverse effects, Humans, Pipecolic Acids/administration & dosage, Pipecolic Acids/adverse effects, Practice Guidelines as Topic, Thrombocytopenia/chemically induced, Thrombocytopenia/prevention & control, Treatment Outcome
Pubmed
Web of science
Create date
16/02/2012 12:00
Last modification date
29/01/2021 6:25
Usage data